

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

[Delete all red text from final paper.]

CONTRIBUTORS – Please bear in mind that the ‘for release’ version of this paper [with highlighted CiC information removed] will be read by the public and published on the NICE website. All confidential information should be highlighted and underlined.

Review of TA TA245; Apixaban for the prevention of venous thromboembolic events in the knee and hip

Final recommendation post consultation
TA245 will be transferred to the ‘static guidance list’.

1. Background

This guidance was issued in January 2012.

At the GE meeting of 20 January 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

TA245 should be transferred to the ‘static guidance list’.

3. Rationale for selecting this proposal

No new or ongoing clinical studies have been found that would suggest an update of the guidance is required.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: GlaxoSmithKline</p> <p>Response to proposal: Request change to matrix</p> <p>Please note that GlaxoSmithKline is no longer the market authorization holder for fondaparinux, it is Aspen. Please could you remove GSK from your list of organisations identified as possible comparator companies and include Aspen.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted.</p>
<p>Respondent: Lifeblood</p> <p>Response to proposal: Agree</p> <p>Agree!</p>	<p>Comment from Technology Appraisals</p> <p>Agreement noted.</p>
<p>Respondent: Genzyme</p> <p>Response to proposal: Request change to matrix</p> <p>Sanofi is listed in the matrix as a named comparator for enoxaparin sodium, for your information enoxaparin is managed within the Sanofi part of the organisation rather than within Genzyme, of which it is a part.</p>	<p>Comment from Technology Appraisals</p> <p>Comment noted.</p>

<p>Respondent: Royal College of Nursing</p> <p>Response to proposal: No comment</p> <p>The Royal College of Nursing invited members who work in this area of health to review and comment on this review proposal consultation.</p> <p>The feedback received suggests that there are no additional comments to make on behalf of the RCN.</p>	<p>Comment from Technology Appraisals</p> <p>Comments noted.</p>
<p>Respondent: Bristol Myers Squibb / Pfizer</p> <p>Response to proposal: Agree</p> <p>We know of no new evidence available that would lead to a change in the existing recommendation, so we agree with your view that TA245 should move to the list of static technology appraisals.</p>	<p>Comment from Technology Appraisals</p> <p>Comment and agreement noted.</p>

Paper signed off by: Janet Robertson, 03 March 2015

Contributors to this paper:

Technical Lead: Mary Hughes

Project Manager: Add name